European Journal of Clinical Pharmacology

, Volume 70, Issue 5, pp 527–530

Safety of combination therapy with milrinone and esmolol for heart protection during percutaneous coronary intervention in acute myocardial infarction

Authors

    • Cardiac Department, National University Heart CenterNational University Health System
    • Yong Loo Lin School of MedicineNational University of Singapore
  • Xin Xu
    • Yuebei People’s Hospital, Shantou University Medical Center
  • Mark Y. Chan
    • Cardiac Department, National University Heart CenterNational University Health System
    • Yong Loo Lin School of MedicineNational University of Singapore
  • Chi-Hang Lee
    • Cardiac Department, National University Heart CenterNational University Health System
    • Yong Loo Lin School of MedicineNational University of Singapore
  • Edgar L. Tay
    • Cardiac Department, National University Heart CenterNational University Health System
    • Yong Loo Lin School of MedicineNational University of Singapore
  • Adrian F. Low
    • Cardiac Department, National University Heart CenterNational University Health System
    • Yong Loo Lin School of MedicineNational University of Singapore
  • Koo Hui Chan
    • Cardiac Department, National University Heart CenterNational University Health System
    • Yong Loo Lin School of MedicineNational University of Singapore
  • Winnie Sia
    • Cardiac Department, National University Heart CenterNational University Health System
  • Liang-Qiu Tang
    • Yuebei People’s Hospital, Shantou University Medical Center
  • Huay Cheem Tan
    • Cardiac Department, National University Heart CenterNational University Health System
    • Yong Loo Lin School of MedicineNational University of Singapore
  • Charles Y. Lui
    • University of Utah VA Hospital
  • Vincent Nguyen
    • Department of Internal Medicine, Cardiology DivisionUniversity of Texas Medical Branch
  • Kenichi Fujise
    • Department of Internal Medicine, Cardiology DivisionUniversity of Texas Medical Branch
    • Department of Internal Medicine, Cardiology DivisionUniversity of Texas Medical Branch
    • Gulf Coast Heart Clinic
Clinical Trial

DOI: 10.1007/s00228-014-1650-9

Cite this article as:
Poh, K., Xu, X., Chan, M.Y. et al. Eur J Clin Pharmacol (2014) 70: 527. doi:10.1007/s00228-014-1650-9

Abstract

Purpose

Ischemia/reperfusion injury remains an untreated clinical problem in patients with acute myocardial infarction (AMI) despite significant advances in emergent revascularization through percutaneous coronary intervention (PCI). Pharmacological intervention for infarct size reduction is unavailable. We have identified that the medications milrinone and esmolol, when administered together at the beginning of the reperfusion, significantly decrease infarct size via reducing reperfusion injury in an experimental model. The present study tested the safety of combination therapy of milrinone and esmolol (M + E) in patients with AMI.

Methods

Sixteen subjects with AMI requiring PCI were consecutively recruited. M + E was intravenously infused simultaneously for 10 min started at 5 min before anticipated angioplasty balloon inflation. Another 16 consecutively recruited AMI patients requiring PCI served as a placebo arm treated per routine clinical protocol. Blood pressure (BP) and heart rate (HR) were monitored continuously during PCI.

Results

M + E combination therapy resulted in a trend of non-significant reduction in BP compared with a control group. There was a modest but significant increase in HR at the later phase of M + E infusion compared with a control group. No significant cardiac arrhythmia was induced during M + E infusion.

Conclusions

The combination therapy with M + E produces a minimal change in hemodynamics and appears safe as an adjunctive therapy to PCI in AMI patients. Further studies are warranted.

Keywords

acute myocardial infarctionesmololmilrinonereperfusion injury

Supplementary material

228_2014_1650_MOESM1_ESM.doc (56 kb)
ESM 1(DOC 56 kb)

Copyright information

© Springer-Verlag Berlin Heidelberg 2014